MovDisordV3, Main, Exploration, bibRecord, 004971

Response to levodopa challenge in Tourette syndrome

Identifieur interne : 004971 ( Main/Exploration ); précédent : 004970; suivant : 004972

Response to levodopa challenge in Tourette syndrome

Auteurs : Kevin J. Black [États-Unis] ; Jonathan W. Mink [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-11.

RBID : ISTEX:A53A348D04CC3B732DB591A0CF668C4F83649089

Descripteurs français

Pascal (Inist)
- Adulte, Chimiothérapie, Dose unique, Epreuve pharmacologique, Etude cas, Gilles de la Tourette syndrome, Lévodopa, Traitement.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (blood), Case study, Chemotherapy, Dopamine (blood), Dopamine (metabolism), Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dopamine Agents (blood), Drug Therapy, Combination, Female, Gilles de la Tourette syndrome, Humans, Levodopa, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (blood), Male, Middle Aged, Pharmacologic test, Pilot Projects, Severity of Illness Index, Single dose, Single-Blind Method, Tourette Syndrome (blood), Tourette Syndrome (drug therapy), Tourette Syndrome (metabolism), Tourette syndrome/treatment, Treatment, Treatment Outcome.
MESH :
- chemical , administration & dosage : Carbidopa, Dopamine Agents, Levodopa.
- chemical , adverse effects : Carbidopa, Dopamine Agents, Levodopa.
- chemical , blood : Carbidopa, Dopamine, Dopamine Agents, Levodopa.
- chemical , metabolism : Dopamine.
- blood : Tourette Syndrome.
- drug therapy : Tourette Syndrome.
- metabolism : Tourette Syndrome.
- Adult, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Single-Blind Method, Treatment Outcome.

Abstract

A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.

Url:

https://api.istex.fr/document/A53A348D04CC3B732DB591A0CF668C4F83649089/fulltext/pdf

DOI: 10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to levodopa challenge in Tourette syndrome</title>
<author><name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name>
</author>
<author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A53A348D04CC3B732DB591A0CF668C4F83649089</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H</idno>
<idno type="url">https://api.istex.fr/document/A53A348D04CC3B732DB591A0CF668C4F83649089/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002C68</idno>
<idno type="wicri:Area/Istex/Curation">002C68</idno>
<idno type="wicri:Area/Istex/Checkpoint">003171</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Black K:response:to:levodopa</idno>
<idno type="wicri:Area/Main/Merge">007268</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:01-0016456</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B12</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000209</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002B25</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Black K:response:to:levodopa</idno>
<idno type="wicri:Area/Main/Merge">007517</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11104204</idno>
<idno type="wicri:Area/PubMed/Corpus">003E61</idno>
<idno type="wicri:Area/PubMed/Curation">003E61</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003E85</idno>
<idno type="wicri:Area/Ncbi/Merge">000390</idno>
<idno type="wicri:Area/Ncbi/Curation">000390</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000390</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Black K:response:to:levodopa</idno>
<idno type="wicri:Area/Main/Merge">007028</idno>
<idno type="wicri:Area/Main/Curation">004971</idno>
<idno type="wicri:Area/Main/Exploration">004971</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Response to levodopa challenge in Tourette syndrome</title>
<author><name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Radiology, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Anatomy and Neurobiology, and Pediatrics, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-11">2000-11</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1194">1194</biblScope>
<biblScope unit="page" to="1198">1198</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A53A348D04CC3B732DB591A0CF668C4F83649089</idno>
<idno type="DOI">10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H</idno>
<idno type="ArticleID">MDS1019</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (blood)</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dopamine (blood)</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (blood)</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Gilles de la Tourette syndrome</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (blood)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pharmacologic test</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Single dose</term>
<term>Single-Blind Method</term>
<term>Tourette Syndrome (blood)</term>
<term>Tourette Syndrome (drug therapy)</term>
<term>Tourette Syndrome (metabolism)</term>
<term>Tourette syndrome/treatment</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term>
<term>Chimiothérapie</term>
<term>Dose unique</term>
<term>Epreuve pharmacologique</term>
<term>Etude cas</term>
<term>Gilles de la Tourette syndrome</term>
<term>Lévodopa</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Missouri (État)</li>
</region>
<settlement><li>Saint-Louis (Missouri)</li>
</settlement>
<orgName><li>École de médecine (Université Washington de Saint-Louis)</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name>
</region>
<name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name>
<name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name>
<name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
<name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004971 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004971 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A53A348D04CC3B732DB591A0CF668C4F83649089
   |texte=   Response to levodopa challenge in Tourette syndrome
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Response to levodopa challenge in Tourette syndrome

Response to levodopa challenge in Tourette syndrome

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.